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With escalating health expenditure and a shrinking purse, there is increased focus on the cost efficacy of still
patented versus generic medications in general, and for atypical antipsychotics in particular. In a recent BMC
Medicine article, Godman and colleagues presented data indicating poor uptake of the off patent atypical
antipsychotic risperidone, arguing for authorities to mandate its greater use. This is under the assumption of clinical
equivalence of atypical antipsychotics. This commentary argues that there are clinically meaningful differences
between atypical antipsychotics and important inter-individual heterogeneity in clinical response and tolerability.
Access to a broad range of atypical antipsychotics enables clinicians to tailor care, taking consideration of differential
efficacy and adverse effects profile in order to meet the needs of individual patients with improved real world
effectiveness of treatment. Restriction of agent choice risks detracting from optimal clinical care, with possible
poorer outcomes and greater costs of care. A balance between encouraging use of cheapest in class agent and
allowing access to various atypical agents for tailored care is likely to produce optimal health outcomes.
Please see related article: http://www.biomedcentral.com/1741-7015/12/98.
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In an economic climate characterised by rising public
debt, sluggish economic growth and rapidly expanding
health care expenditures, there is increasing pressure on
restraining the pace of growth of the health care budget.
Pharmaceutical expenditure is a large and growing seg-
ment of this budget and an attractive target for cost reduc-
tion. In an article recently published in BMC Medicine,
Godman and colleagues [1] present data from an inter-
national retrospective association study of risperidone
prescribing rates 20 months before and 20 months af-
ter cheaper generic brands became available in several
European countries. Interestingly, their data indicate that
once generic risperidone was available, it was prescribed
less (as a proportion of all atypical antipsychotic scripts),
and there was a wide variance between countries in the
proportion of risperidone scripts that were generic versus
brand name. Furthermore, among newly initiated patients* Correspondence: a.singh@deakin.edu.au
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unless otherwise stated.prescribed atypical antipsychotics there was no increased
prescribing of generic risperidone when it may have been
a valid treatment option. The authors argue that their data
have significant implications for health care costs and
suggest that health authorities encourage prescribing
of cheaper generics versus allowing prescribers to tailor
treatment to patient needs based on differential medica-
tion side effect and efficacy profiles. We submit that third
party payers mandating the use of cheaper generic atypical
antipsychotics as first line agents in schizophrenia and bi-
polar disorders raises important but complex issues meri-
ting debate.
Differential efficacy profiles of atypical antipsychotics
Atypical antipsychotics are now among the most widely
used agents and the bulk of this use - at least in western
countries - is for non-psychotic indications, principally
mood disorders. The efficacy of individual atypical anti-
psychotic agents varies by both condition (schizophrenia
or bipolar disorder) and phase of illness (particularly bipo-
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tics in the treatment of schizophrenia [2], but due to side
effect and toxicity profile is not used as a first line agent
[3]. Subtle differences in efficacy between other atypical
antipsychotics in the treatment of schizophrenia - particu-
larly in improving negative symptoms - arguably exist, but
it is unclear whether this is an artefact of methodological
variance [2,4]. Importantly, while atypical antipsychotics
have equal efficacy in treating mania, they clearly have dif-
ferential efficacy in the depressive phase of bipolar dis-
order [5,6], with agents such as quetipine and lurasidone
demonstrating efficacy while aripiprazole, ziprasidone and
risperidone have failed to show consistent benefit and,
hence, are not recommended for the management of the
depressive phase of bipolar disorder [6]. Similarly, in uni-
polar depression, only quetiapine has been shown to be ef-
fective in monotherapy. Atypical antipsychotics are also
widely used as adjuncts to antidepressants to treat re-
fractory unipolar major depression, and here again, while
quetiapine, aripiprazole, risperidone and olanzapine have
efficacy based on meta-analytical data, the number needed
to treat for response and remission are much higher and
the number needed to harm are much lower for olanza-
pine compared with other atypical antipsychotics [7]. Fur-
thermore, another atypical antipsychotic ziprasidone does
not have demonstrated efficacy [8,9]. Differential efficacy
of atypical antipsychotics for other clinical uses has been
less thoroughly investigated, but risperidone may have
utility in dementia associated agitation and obsessive com-
pulsive disorder, but poorer efficacy for generalized anx-
iety disorder than some other atypical agents, such as
quetiapine [10]. Indeed, this inconsistent pattern of effi-
cacy of antipsychotic agents in non-psychotic disorders ar-
gues strongly against the presence of a class effect. These
agents, in reality, have markedly divergent pharmaco-
dynamics and pharmacokinetics and, while there is con-
sensus that activity against dopamine type 2 receptors is
necessary for antipsychotic efficacy [11], there is consider-
able uncertainty as to which of the multiplicity of actions
these agents have may drive their effects in mood disor-
ders [12,13].
Differential tolerability profiles of atypical antipsychotics
Atypical antipsychotics also have widely differing side ef-
fect and tolerability profiles. This is of critical clinical
importance as tolerability is one factor driving adherence
[14], and medication adherence markedly influences
both clinical course and cost of care [15,16]. In the case
of risperidone, more extrapyramidal side effects, greater
prolactin elevation, and greater weight gain than with
some other atypical antipsychotics have been described
in recent high profile reviews [2,17]. Elevation of prolac-
tin appears to be particularly marked with risperidone
compared to other atypical agents [2] and is associatedwith hypogonadism, reproductive dysfunction, gyneco-
mastia and bone loss [18]. Osteoporosis and fracture
risk is an adverse effect of diverse psychotropic agents
attracting increasing recent attention, and one where
very clear between-agent differences are apparent [19,20].
Risperidone is, however, less associated with the metabolic
syndrome than other agents, particularly olanzapine, que-
tiapine and clozapine [6]. Trend level differences for all
cause medication discontinuation have been noted with
risperidone, trending toward greater discontinuation than
some other atypical agents – putatively due to differential
side effect profiles and tolerability [2,17]. As adverse
events are idiosyncratic and unpredictable, the avail-
ability of various atypical antipsychotics enables patient
and prescriber to tailor treatment based on differential
side effects profile, and this may enhance adherence [21].
This clinical need is reflected in international clinical prac-
tice guidelines on the management of schizophrenia and
bipolar disorder – with several atypical agents considered
first line options in patient care [3,6].
Conclusions
Finite health resources make cost effective use of phar-
maceuticals an important societal issue. Atypical anti-
psychotics have differing tolerability and efficacy profiles.
Effectiveness in naturalistic settings is highly dependent
on subjective efficacy as well as on adherence, which in
turn is related to long and short term side effect profiles.
While access to cheaper generic atypical antipsychotics
offers an opportunity for more cost effective care, it is
not without risks. Mandating switching to a generic aty-
pical antipsychotic without any corresponding clinical
indication may result in increased risk of relapse, re-
duced adherence, poorer outcomes and greater ultimate
health care costs [22,23]. Reducing access to a range of
atypical agents as first line treatment will hamper tailor-
ing of medication to individual patient needs and prefe-
rence, reducing clinical effectiveness and making it more
difficult for clinicians to follow current best practice
guidelines [3,6]. Nevertheless, there will be some clinical
instances where use of a more cost-effective generic
atypical agent (either first line or as switch to agent)
may be appropriate, and ways for third party payers
to encourage such behaviour merit further exploration.
In the absence of data, we urge policy makers to strike a
balance between tailored effective care (with choice of
atypical antipsychotic agent) versus mandated use of
cheapest in class agent. To obtain the data necessary for
evidence-based policy, it would be useful to invest in
comparative effectiveness studies that focus on: 1) out-
comes of tailored versus mandated care, and 2) suf-
ficiently powered cluster-randomized studies of key
atypical antipsychotics. Our patients’ health deserves no
less.
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